These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7727383)

  • 21. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
    Ritke MK; Yalowich JC
    Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.
    Chan VT; Ng SW; Eder JP; Schnipper LE
    J Biol Chem; 1993 Jan; 268(3):2160-5. PubMed ID: 8380592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
    Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
    Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH
    Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
    Bugg BY; Danks MK; Beck WT; Suttle DP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
    Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
    Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.
    Hosking LK; Whelan RD; Shellard SA; Davies SL; Hickson ID; Danks MK; Hill BT
    Int J Cancer; 1994 Apr; 57(2):259-67. PubMed ID: 7908897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
    Ades S; Maxfield LF; Gould CJ; Jones GK; Levy SB
    Int J Oncol; 2006 Mar; 28(3):747-53. PubMed ID: 16465381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
    Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Oct; 92(10):1133-7. PubMed ID: 11676865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
    Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
    Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.